Showing results (1-10 of 100) with videos related to
Sort By:
Pageof 10
Muscle & Nerve|November 25, 2014
Optimizing IgG therapy in chronic autoimmune neuropathies: a hypothesis driven approachMelvin Berger, Jeffrey A AllenJournal of the Peripheral Nervous System : JPNS|March 25, 2018
Individualized immunoglobulin therapy in chronic immune-mediated peripheral neuropathiesJeffrey A Allen, Melvin Berger, Luis Querol, et al.Journal of Clinical Immunology|October 3, 2007
A multicenter, prospective, open label, historically controlled clinical trial to evaluate efficacy and safety in primary immunodeficiency diseases (PID) patients of Flebogamma 5% DIF, the next generation of FlebogammaMelvin Berger, Current Opinion in Allergy and Clinical Immunology|October 6, 2011
Choices in IgG replacement therapy for primary immune deficiency diseases: subcutaneous IgG vs. intravenous IgG and selecting an optimal doseMelvin BergerJournal of Clinical Immunology|June 7, 2011
Incidence of infection is inversely related to steady-state (trough) serum IgG level in studies of subcutaneous IgG in PIDDMelvin BergerImmunology and Allergy Clinics of North America|April 22, 2008
Principles of and advances in immunoglobulin replacement therapy for primary immunodeficiencyMelvin BergerTransfusion|December 12, 2018
Antibodies to vaccine antigens in pooled polyclonal human IgG productsMelvin BergerClinical Immunology (Orlando, Fla.)|June 23, 2004
Subcutaneous immunoglobulin replacement in primary immunodeficienciesMelvin BergerAllergy and Asthma Proceedings|March 16, 2002
Inflammatory mediators in cystic fibrosis lung diseaseMelvin BergerPageof 10